4//SEC Filing
AVALON PHARMACEUTICALS INC 4
Accession 0001209191-08-005210
CIK 0001162192operating
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 8:41 PM ET
Size
28.3 KB
Accession
0001209191-08-005210
Insider Transaction Report
Form 4
Carter Kenneth C
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2008-01-17$2.53/sh−200$506→ 22,643 total - Sale
Common Stock
2008-01-17$2.45/sh−732$1,793→ 23,143 total - Sale
Common Stock
2008-01-17$2.50/sh−300$750→ 22,843 total - Purchase
Common Stock
2008-01-23$2.49/sh+500$1,244→ 21,675 total - Purchase
Common Stock
2008-01-23$2.60/sh+800$2,077→ 22,675 total - Purchase
Common Stock
2008-01-23$2.61/sh+1,036$2,708→ 23,711 total - Purchase
Common Stock
2008-01-23$2.60/sh+164$427→ 23,875 total - Purchase
Common Stock
2008-01-23$2.48/sh+632$1,570→ 21,175 total - Purchase
Common Stock
2008-01-23$2.65/sh+1,400$3,710→ 20,443 total - Sale
Common Stock
2008-01-17$2.63/sh−400$1,052→ 22,043 total - Purchase
Common Stock
2008-01-23$2.46/sh+100$246→ 20,543 total
Holdings
- 3,750(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]3,482 shares were inadvertently sold on January 17, 2008. On January 23, 2008, the reporting person executed a purchase for the same number of shares. The reporting person has agreed to pay to Avalon Pharmaceuticals, Inc., upon settlement of the sale, the full amount of any profit realized in connection with the short-swing transaction, less transaction costs. The reporting person expects the profit to equal $0.
- [F2]The reporting person disclaims beneficial ownership of these securities, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
Documents
Issuer
AVALON PHARMACEUTICALS INC
CIK 0001162192
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001162192
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 8:41 PM ET
- Size
- 28.3 KB